Executive Team

Mr. McFadden brings more than 30 years of successful leadership experience spanning pre-IND drug discovery through the commercialization and has launched over a dozen therapies in neurology, psychiatry, endocrinology and urology. He has over 16 years’ experience in Neuroscience. Previous leadership roles have included Chief Commercial Officer at MPower Health, Chief Commercial Officer at Urovant Sciences (Nasdaq: UROV), and SVP Sales and Marketing at Avanir Pharmaceuticals (Nasdaq: AVNR). Prior to these roles, Mr. McFadden held leadership roles at Amylin Pharmaceuticals (Nasdaq: AMLN) and Pharmacia. He serves on advisory boards at MPower Health and MindLab.

Ms. D'Angelo brings 25 years in pharmaceuticals marketing, sales, and operations, with broad reaching clinical experience across 15 products within nine therapeutic areas. She has deep experience in small and large organizations from pre-commercialization to launch and post-launch, with demonstrated success building commercialization and launch plans for US and global markets, and managing P&L. She has developed and led 20+ launch plans and successfully launched 15 products, new indications, and line extensions, in varying leadership roles. She was recognized as a 2023 PharmaVoice Top 100 Industry Leader, Medical Marketing & Media's (MM+M) 2022 Woman of Distinction, MM+M's 2017 Woman to Watch, and was selected as one of Pharmaceutical Executive's Emerging Pharma Leaders for 2020.

Mr. Du brings over 15 years' experience to Alpha Cognition in leadership roles in both finance and accounting.. Prior to Mr. Du was Sr. Vice President of Accounting and Administration at Amplify Surgical, a medical device company focused on developing innovative endoscopic surgical techniques and spinal implant technologies, where he led the finance and accounting functions, as well as administrative roles including HR, payroll, compliance, corporate legal, and investor relations. During his tenure there, he was instrumental in helping the company achieve consistent positive EBIDTA and profitability, along with doubling average daily operating liquidity. Mr. Du was also VP of Finance and Senior Corporate Controller at HUYABIO International, a leader in globalizing Chinese pharmaceutical innovation, where he established the commercial accounting policy for the company's product launch in Japan. Prior to HUYABIO, Mr. Du served in leadership roles at Eledon Pharmaceuticals (formerly Novus Therapeutics), a publicly traded clinical-stage biopharmaceutical company, United Auto Credit, and at Avanir. He earned his B.A. in Economics-Accounting from Claremont McKenna College. Mr. Du is a licensed Certified Public Accountant (CPA) in the State of California.

Dr. Kay is the Co-founded the Company’s original company Neurodyn Life Sciences (NLS), in August 2006 and acted as NLS’s Chief Scientific Officer since that time. In 2017 he assumed the role of Chief Scientific Officer at ACI. He brings more than 30 years of experience in the development and characterization of animal models of neurological diseases, and 7 years of early-stage Central Nervous System clinical development experience in. He is a grant recipient of the Michael J. Fox Foundation and has received funding from numerous agencies for research and product development programs.